Recursion Pharmaceuticals, Inc. (RXRX) Misses Q1 EPS by 1c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q1 EPS of ($0.50), $0.01 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $14.75 million versus the consensus estimate of $14.98 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Innovaro (INV) Misses Q2 EPS by 9c
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c